Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit.
Wojciech KrajewskiMarco MoschiniŁukasz NowakSlawomir PoletajewAndrzej TukiendorfLuca AfferiJeremy Yuen Chun TeohTim MuilwijkSteven JoniauAlessandro TafuriAlessandro AntonelliAlessandra GozzoAndrea MariEttore Di TrapaniKees HendricksenMario Álvarez-MaestroAndrea Rodriguez SerranoGiuseppe SimoneStefania ZamboniClaudio SimeoneMaria Cristina MarconiRiccardo MastroianniGuillaume PloussardPaweł RajwaEkaterina LaukhtinaAleksandra Zdrojowy-WełnaAnna KołodziejAndrzej ParadyszKarl TullyJoanna KrajewskaRadosław PiszczekEvanguelos XylinasRomuald ZdrojowyPublished in: Journal of clinical medicine (2020)
Our results suggest that there might be no difference in recurrence-free survival and progression-free survival rates, regardless of whether patients have reTURB performed before or after BCG induction.